{
    "organizations": [],
    "uuid": "6051d35fb234a10af1a3151ee65803f0cbdc0301",
    "author": "",
    "url": "https://www.reuters.com/article/brief-vaxil-completes-oversubscribed-fin/brief-vaxil-completes-oversubscribed-financing-to-advance-cancer-immunotherapy-research-idUSASB0C2ZD",
    "ord_in_thread": 0,
    "title": "BRIEF-Vaxil Completes Oversubscribed Financing To Advance Cancer Immunotherapy Research",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 30, 2018 / 1:43 PM / in 7 minutes BRIEF-Vaxil Completes Oversubscribed Financing To Advance Cancer Immunotherapy Research Reuters Staff 1 Min Read \nJan 30 (Reuters) - Vaxil Bio Ltd: \n* VAXIL COMPLETES OVERSUBSCRIBED FINANCING TO ADVANCE ITS CANCER IMMUNOTHERAPY RESEARCH AND DEVELOPMENT Source text for Eikon: Further company coverage:",
    "published": "2018-01-30T15:41:00.000+02:00",
    "crawled": "2018-01-30T15:52:40.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "completes",
        "oversubscribed",
        "financing",
        "advance",
        "cancer",
        "immunotherapy",
        "research",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "vaxil",
        "bio",
        "ltd",
        "vaxil",
        "completes",
        "oversubscribed",
        "financing",
        "advance",
        "cancer",
        "immunotherapy",
        "research",
        "development",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}